rs5030832
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PM1PM2PM5PP3_StrongPP5_Very_Strong
The NM_000551.4(VHL):c.362A>G(p.Asp121Gly) variant causes a missense change. The variant allele was found at a frequency of 0.000000684 in 1,461,678 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. D121N) has been classified as Pathogenic.
Frequency
Consequence
NM_000551.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
VHL | NM_000551.4 | c.362A>G | p.Asp121Gly | missense_variant | 2/3 | ENST00000256474.3 | |
VHL | NM_001354723.2 | c.*18-3252A>G | intron_variant | ||||
VHL | NM_198156.3 | c.341-3252A>G | intron_variant | ||||
VHL | NR_176335.1 | n.691A>G | non_coding_transcript_exon_variant | 3/4 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
VHL | ENST00000256474.3 | c.362A>G | p.Asp121Gly | missense_variant | 2/3 | 1 | NM_000551.4 | P1 |
Frequencies
GnomAD3 genomes ? Cov.: 32
GnomAD4 exome AF: 6.84e-7 AC: 1AN: 1461678Hom.: 0 Cov.: 31 AF XY: 0.00 AC XY: 0AN XY: 727130
GnomAD4 genome ? Cov.: 32
ClinVar
Submissions by phenotype
Von Hippel-Lindau syndrome Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Feb 05, 2016 | Variant summary: c.362A>G affects a conserved nucleotide, resulting in amino acid change from Asp to Gly. 4/4 in-silico tools predict this variant to be damaging. This variant was not found in 121412 control chromosomes. This variant has been reported in multiple VHL patients. Functional studies showed that variant retained most of the proteins abilities, including its interaction with HIF in vitro and the downstream down-regulation of gene expression controlled by HIF, as well as supporting HIF-1 ubiquitination (less than that observed for wild-type pVHL), and the interaction with elongin C. (Hansen_2002, Ruiz-Llorente_2004). However, there is also study showed that only partial interaction with elongin C is retained and the recruiting a complex containing the essential human VBCE3 ubiquitin ligase components CHL2 and ROC1 is detected (Hacker _2008). Considering all these studies were performed in vitro, the disease mechanism of this variant remains unclear. Variants D121G, D121N both are listed as disease mutation in HGMD and have been reported in multiple publications suggesting the codon 121 might be a hotspot for mutations. Taken together, this variant was classified as a Pathogenic. - |
Pathogenic, no assertion criteria provided | clinical testing | Genomic Diagnostic Laboratory, Division of Genomic Diagnostics, Children's Hospital of Philadelphia | Feb 26, 2016 | - - |
Von Hippel-Lindau syndrome;C1837915:Chuvash polycythemia Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Invitae | Sep 11, 2020 | This sequence change replaces aspartic acid with glycine at codon 121 of the VHL protein (p.Asp121Gly). The aspartic acid residue is moderately conserved and there is a moderate physicochemical difference between aspartic acid and glycine. This variant is not present in population databases (ExAC no frequency). This variant has been observed in several individuals affected with, or with clinical features of von Hippel-Lindau syndrome (PMID: 16572651, 7977367, 9681856, 15300849, 20660572, 11409863, 8956040). ClinVar contains an entry for this variant (Variation ID: 223200). Experimental studies have shown that this missense change affects nuclear export of the VHL protein and its effect on downstream target HIF (PMID: 17967880, 11865071, 21715564). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site, but this prediction has not been confirmed by published transcriptional studies. This variant disrupts the p.Asp121 amino acid residue in VHL. Other variants that disrupt this residue have been observed in affected individuals (PMID: 16142346, 25557216), suggesting that it is a clinically significant residue. As a result, variants that disrupt this residue are likely to be causative of disease. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. - |
not provided Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | PreventionGenetics, part of Exact Sciences | Aug 16, 2017 | - - |
Hereditary cancer-predisposing syndrome Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Oct 08, 2021 | The p.D121G variant (also known as c.362A>G), located in coding exon 2 of the VHL gene, results from an A to G substitution at nucleotide position 362. The aspartic acid at codon 121 is replaced by glycine, an amino acid with similar properties. This variant has been identified in multiple individuals with a clinical diagnosis or suspicion of von-Hippel-Lindau (VHL) syndrome (Ruiz-Llorente S et al. Hum Mutat, 2004 Feb;23:160-9; Erlic Z et al. Endocr Relat Cancer, 2010 Dec;17:875-83; Rasmussen A et al. J Neurosurg, 2006 Mar;104:389-94). In functional studies, this alteration was shown to decrease nuclear export of the VHL protein and to reduce ability to degrade downstream target HIF-alpha (Khacho M et al. Mol Cell Biol, 2008 Jan;28:302-14; Rechsteiner MP et al. Cancer Res, 2011 Aug;71:5500-11). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on internal structural analysis, D121G is moderately destabilizing to the local structure and more disruptive than known pathogenic variants in the region (Ambry internal data). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at